Zai Lab Ltd (ZLAB)
NASDAQ:ZLAB
Want to see ZLAB full AI Analyst Report?
Top Page
Zai Lab
(NASDAQ:ZLAB)
Select Model
Select Model
Rating:44Neutral
Price Target:
$16.00
▼(-33.86% Downside)
Action:Reiterated
Date:06/08/26
The score is held down mainly by weak financial performance (ongoing losses and cash burn) and bearish technical signals (below key moving averages with negative MACD). The latest earnings call provides partial offset through strong pipeline momentum and a solid cash position, while valuation offers limited support due to negative earnings and no dividend.
Positive Factors
Zoci clinical efficacy & registrational path
Robust intracranial and systemic response rates position Zoci as potentially best-in-class in select NET/SCLC settings. A clear registrational Phase III timeline with H1 2027 enrollment completion and an interim for accelerated filing materially improves the probability of a durable new product franchise that could transform mid‑term revenue and de‑risk the oncology portfolio.
Negative Factors
Persistent negative cash flow
Operating and free cash flow remain negative across all periods, and TTM free cash flow deteriorated, signaling that reported earnings improvements have not yet translated into stable cash generation. This structural cash burn creates ongoing funding risk and potential dilution if clinical timelines or launches slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Zoci clinical efficacy & registrational path
Robust intracranial and systemic response rates position Zoci as potentially best-in-class in select NET/SCLC settings. A clear registrational Phase III timeline with H1 2027 enrollment completion and an interim for accelerated filing materially improves the probability of a durable new product franchise that could transform mid‑term revenue and de‑risk the oncology portfolio.
Read all positive factors
Zai Lab (ZLAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.87B
Dividend YieldN/A
Average Volume (3M)801.32K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth8.57%
EPS Growth35.12%
CountryUS
Employees1,869
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.63
Shares Outstanding113,412,800
10 Day Avg. Volume916,624
30 Day Avg. Volume801,319
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.70
Price to Sales (P/S)4.20
P/FCF Ratio-12.16
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit5.63
Enterprise Value/Ebitda-9.33
Forecast
1Y Price Target
$32.40Price Target Upside33.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$458.23M
Zai Lab Business Overview & Revenue Model
Company Description
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmu...
How the Company Makes Money
Zai Lab primarily makes money through (1) product sales of its commercial-stage medicines in its licensed or owned territories, and (2) collaboration-related revenue tied to partnerships (e.g., licensing arrangements), which can include upfront pa...
Zai Lab Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful clinical and strategic progress — notably strong Zoci intracranial and extrapulmonary NET responses, advancing global registrational plans, high-value collaborations (Amgen, Boehringer Ingelheim), an expanding pipeline (ZL-1503, ZL‑6201, ZL‑1311), and a solid cash position ($761.3M). These positives are tempered by near-term commercial and financial headwinds: Q1 product revenue declined 6% to $99.6M, loss from operations widened 23% to $69.4M, ZEJULA weakness from generic competition, VYVGART pricing pressure (12% discount), and XACDURO supply constraints. Overall, the call balances strong long‑term pipeline momentum and strategic positioning against short-term revenue and operational pressures, with management expecting sequential improvement and a return to growth in 2027.Positive Updates
Compelling Zoci clinical data — strong intracranial activity
In extensive-stage small cell lung cancer at the 1.6 mg/kg dose, Zoci showed a confirmed intracranial overall response rate of 62.5% and a best intracranial response approaching 69% (including 4 complete responses). Grade ≥3 treatment-related adverse events were ~16%. These intracranial responses and favorable safety profile were presented as best-in-class signals.
Negative Updates
Quarterly revenue decline
Total product revenue declined 6% year-over-year to $99.6 million in Q1 2026, and management expects near-term pressure for full-year 2026 with return to growth anticipated in 2027.
Read all updates
Q1-2026 Updates
Positive
Negative
Compelling Zoci clinical data — strong intracranial activity
In extensive-stage small cell lung cancer at the 1.6 mg/kg dose, Zoci showed a confirmed intracranial overall response rate of 62.5% and a best intracranial response approaching 69% (including 4 complete responses). Grade ≥3 treatment-related adverse events were ~16%. These intracranial responses and favorable safety profile were presented as best-in-class signals.
Read all positive updates
Company Guidance
The company’s guidance included both clinical and near‑term financial/timing metrics: Q1 total product revenue was $99.6M (down 6% YoY) with sequential improvement expected over the next nine months but full‑year 2026 revenue pressure and a return to growth forecast for 2027; loss from operations rose 23% to $69.4M, R&D spend increased ~8% YoY, SG&A was slightly higher, and cash on hand was $761.3M; commercial notes included VYVGART double‑digit volume growth YoY but a 12% NRDL‑related price discount and biologic penetration in gMG of ~15%, while XACDURO faces supply constraints through the year with local manufacturing expected in 2027 and KarXT launching in Q2 2026. Clinical/timing guidance: Zoci’s registrational Phase III (DLLEVATE) is enrolling and on track to complete enrollment in H1 2027 with an interim analysis and potential accelerated approval filing in 2027 and a first global BLA submission planned for late 2027; Zoci clinical signals include intracranial confirmed ORR 62.5% (best intracranial ~69% with 4 CRs), Grade ≥3 TRAEs ~16%, extrapulmonary NEC confirmed ORR 38.2% (vs ~18% for current regimens) and ~68% systemic response in second line at 1.6 mg/kg, with Amgen triplet cohorts enrolling and BI studies to follow. Other pipeline/timing metrics: ZL‑1503 Phase I/Ib healthy volunteer and AD cohort data expected in H2 2026 (with Phase II planned), ZL‑1311 to enter clinic by year‑end 2026, ZL‑6201 already in clinic, Tumor Treating Fields MAA submitted with approval expected by year‑end 2026, Tivdak potential approval “in the coming months,” and partner Vertex’s povetacicept showed ~50% proteinuria reduction meeting primary and all secondary endpoints.Zai Lab Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
63
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 453.28M | 460.16M | 398.99M | 266.72M | 215.04M | 144.31M |
| Gross Profit | 262.51M | 269.07M | 251.13M | 170.90M | 141.02M | 92.07M |
| EBITDA | -158.45M | -158.25M | -234.57M | -365.11M | -434.84M | -689.46M |
| Net Income | -178.12M | -175.54M | -257.10M | -334.62M | -443.29M | -704.47M |
Balance Sheet | ||||||
| Total Assets | 1.10B | 1.17B | 1.19B | 1.04B | 1.22B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 661.32M | 689.57M | 779.67M | 806.45M | 1.01B | 1.41B |
| Total Debt | 231.91M | 224.26M | 153.47M | 15.15M | 20.39M | 15.54M |
| Total Liabilities | 433.76M | 456.88M | 344.86M | 240.18M | 174.54M | 230.00M |
| Stockholders Equity | 661.98M | 715.50M | 840.90M | 796.12M | 1.05B | 1.38B |
Cash Flow | ||||||
| Free Cash Flow | -129.23M | -158.89M | -276.39M | -206.67M | -392.63M | -568.18M |
| Operating Cash Flow | -101.00M | -150.79M | -214.87M | -198.18M | -367.64M | -549.23M |
| Investing Cash Flow | -40.55M | 307.87M | -375.19M | -10.78M | 420.02M | 249.96M |
| Financing Cash Flow | 34.78M | 72.35M | 349.89M | -6.43M | -1.73M | 820.20M |
Zai Lab Technical Analysis
Negative
24.19
Price Trends
20.20
Negative
19.39
Negative
22.46
Negative
Market Momentum
-1.01
Positive
31.41
Neutral
20.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZLAB, the sentiment is Negative. The current price of 24.19 is above the 20-day moving average (MA) of 18.47, above the 50-day MA of 20.20, and above the 200-day MA of 22.46, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 31.41 is Neutral, neither overbought nor oversold. The STOCH value of 20.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZLAB.
Zai Lab Risk Analysis
Zai Lab disclosed 101 risk factors in its most recent earnings report. Zai Lab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zai Lab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $8.90B | 39.27 | 19.25% | ― | 25.15% | 79.56% | |
72 Outperform | $3.72B | 9.85 | 35.65% | ― | 9.93% | 61.40% | |
56 Neutral | $5.89B | ― | 99.84% | ― | -53.34% | -130.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.87B | -10.29 | -24.29% | ― | 8.57% | 35.12% |
* Healthcare Sector Average
ZLAB
Zai Lab
16.48
-21.39
-56.48%
ACAD
ACADIA Pharmaceuticals
21.70
-0.60
-2.69%
PTCT
PTC Therapeutics
70.87
19.18
37.11%
KRYS
Krystal Biotech
301.76
165.68
121.75%
Zai Lab Corporate Events
Business Operations and StrategyExecutive/Board Changes
Zai Lab Announces Leadership Change as COO Departs
Negative
May 22, 2026
On May 18, 2026, Zai Lab Limited’s board determined that President and Chief Operating Officer Josh Smiley would cease serving in those roles, with his last day at the company set for May 22, 2026. The operational responsibilities tied to hi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.